{"url_path":"/sec/nrxpw/8-k/2026-06-02/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1719406/0001437749-26-019196-index.html","accession_number":"0001437749-26-019196","cik":"0001719406","ticker":"NRXP","issuer_name":"NRX Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1719406/0001437749-26-019196-index.html","primary_entity_key":"0001719406","primary_entity_name":"NRX Pharmaceuticals, Inc."},"word_count":120,"has_tables":true,"body_markdown":"**Item 8.01.**\n\n**Other Events.**\n\n \n\nOn June 2, 2026, NRx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it intends to offer shares of its common stock, par value $0.001 per share (“Common Stock”) in an underwritten public offering (the “Offering”).\n\n \n\nA copy of the press release is attached hereto as Exhibit 99.1.\n\n \n\nThis Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."}